Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround

Executive Summary

A CHMP about turn on Takeda's Ninlaro (ixazomib) for multiple myeloma means the Japanese firm is back on track to compensate for lost revenues from the impending patent expiry of key product Velcade. However, the Japanese firm will have a tough time ensuring Ninlaro is not overshadowed by rivals.


Related Content

Another Sea Change In Myeloma Promised By New Therapies, Combos
Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned
Multiple Myeloma Market Snapshot: New Drugs And Big Changes


Related Companies